Comparing the quantity and quality of randomised placebo-controlled trials of antibiotics for acute respiratory, urinary, and skin and soft tissue infections: a scoping review.
anti-bacterial agent
primary health care
randomised controlled trials
respiratory tract infections
skin and soft tissues infections
urinary tract infections
Journal
BJGP open
ISSN: 2398-3795
Titre abrégé: BJGP Open
Pays: England
ID NLM: 101713531
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
12
02
2020
accepted:
09
03
2020
pubmed:
1
10
2020
medline:
1
10
2020
entrez:
30
9
2020
Statut:
epublish
Résumé
The management of acute respiratory infections (ARIs), urinary tract infections (UTIs), and skin and soft tissue infections (SSTIs) should be guided by high quality evidence. To compare the quantity and quality of randomised placebo-controlled trials of antibiotics for ARIs, UTIs, and SSTIs. A scoping review of the literature was performed using comprehensive search strategies. PubMed and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for published studies from inception until 17 April 2019. Randomised controlled trials (RCTs) that compared participants in primary care or in the community who had uncomplicated acute ARI, UTI, or studies, and were randomised to antibiotic or placebo (or no active treatment), were eligible for inclusion. Two groups of researchers independently screened articles for inclusion, extracted data, and assessed the quality of included studies. A total of 108 eligible studies were identified: 80 on ARI, eight on UTI, and 20 on SSTI. The quality of studies varied with unclear risk of bias (RoB) prevalent in many domains. There was a gradual improvement in the quality of trials investigating ARIs over time, which could not be assessed in SSTI and UTI studies. This review highlights a sparsity of trials assessing the effectiveness of antibiotics in people with UTIs and SSTIs, compared to trials targeting ARIs. This gap in the evidence needs to be addressed by conducting further high quality trials on the effects of antibiotics in patients with UTI and SSTI.
Sections du résumé
BACKGROUND
BACKGROUND
The management of acute respiratory infections (ARIs), urinary tract infections (UTIs), and skin and soft tissue infections (SSTIs) should be guided by high quality evidence.
AIM
OBJECTIVE
To compare the quantity and quality of randomised placebo-controlled trials of antibiotics for ARIs, UTIs, and SSTIs.
DESIGN & SETTING
METHODS
A scoping review of the literature was performed using comprehensive search strategies.
METHOD
METHODS
PubMed and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for published studies from inception until 17 April 2019. Randomised controlled trials (RCTs) that compared participants in primary care or in the community who had uncomplicated acute ARI, UTI, or studies, and were randomised to antibiotic or placebo (or no active treatment), were eligible for inclusion. Two groups of researchers independently screened articles for inclusion, extracted data, and assessed the quality of included studies.
RESULTS
RESULTS
A total of 108 eligible studies were identified: 80 on ARI, eight on UTI, and 20 on SSTI. The quality of studies varied with unclear risk of bias (RoB) prevalent in many domains. There was a gradual improvement in the quality of trials investigating ARIs over time, which could not be assessed in SSTI and UTI studies.
CONCLUSION
CONCLUSIONS
This review highlights a sparsity of trials assessing the effectiveness of antibiotics in people with UTIs and SSTIs, compared to trials targeting ARIs. This gap in the evidence needs to be addressed by conducting further high quality trials on the effects of antibiotics in patients with UTI and SSTI.
Identifiants
pubmed: 32994206
pii: bjgpopen20X101082
doi: 10.3399/bjgpopen20X101082
pmc: PMC7606140
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright © 2020, The Authors.
Références
Int J Antimicrob Agents. 2011 Dec;38 Suppl:21-35
pubmed: 22000072
Res Synth Methods. 2018 Dec;9(4):602-614
pubmed: 29314757
J Antimicrob Chemother. 2014 Jan;69(1):234-40
pubmed: 23887867
Lancet. 2005 Feb 12-18;365(9459):579-87
pubmed: 15708101
J Infect. 2009 Feb;58(2):91-102
pubmed: 19195714
Evid Based Med. 2017 Jun;22(3):88-92
pubmed: 28554944
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):ii2-ii10
pubmed: 29490062
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
J Am Board Fam Pract. 2004 Jan-Feb;17(1):59-67
pubmed: 15014055
Cochrane Database Syst Rev. 2012 Jan 18;1:CD003261
pubmed: 22258953
JAMA. 2014 Oct 22-29;312(16):1677-84
pubmed: 25335150